Skip to Main Content

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Conditions

Colon | Other Digestive Organ | Rectum

Phase 1a/1b

What is the purpose of this trial?

This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).

  • Trial with
    Arcus Biosciences, Inc.
  • Start Date
    02/06/2019
  • End Date
    11/29/2020

For more information about this study, contact:

Christina Wiess

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    01/20/2020
  • Study HIC
    #2000024289